Emkay Global Financial Services Ltd. Share Price

Overview

Emkay Global Financial Services Ltd. share price is currently ₹248.27, up by ₹3.31 (1.35%) from its previous closing price of ₹244.96. The share price has declined -1.86% over the past month and declined -16.85% over the past year. The stock's 52-week low and high are ₹183.13 and ₹323.20, respectively. Emkay Global Financial Services Ltd. has a market capitalisation of ₹ 694.92 Cr. The share price was last updated on 20 Nov 2026, 02:26 PM IST.

Emkay Global Financial Services Ltd.
Emkay Global Financial Services Ltd.
EMKAY
 ₹0.00
 ₹3.31
1.35%
Finance
 ₹0.00(%)1D

Updated: 20 Nov 2026, 02:26:32 pm IST

Market Data

Open Price

 ₹247.43

Prev. Close

 ₹244.96
 ₹242.36

Day Low

 ₹250.22

Day High

 ₹183.13

52 Week Low

 ₹323.20

52 Week High

FinanceFinance - Stock Broking
CategoryMicro Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

13.60

Sector PE

19.03

PB Ratio

2.04

Sector PB

2.66

EPS

18.25

Dividend Yield

0.79

Today's Volume

43.156 K

5 Day Avg. Volume

61.808 K

PEG Ratio

-0.18

Market Cap.

₹ 694.92 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 15% at ₹1.5/Share
03-Aug-202603-Aug-2026
DividendsSpecial Dividend of 25% at ₹2.5/Share
04-Aug-202504-Aug-2025
DividendsFinal Dividend of 15% at ₹1.5/Share
04-Aug-202504-Aug-2025

Mutual Fund Ownership

Mutual Fund Ownership will be available shortly.

About Emkay Global Financial Services Ltd. 👋

Emkay Global Financial Services Limited is an India-based financial services company, which offers a range of transactional and advisory services encompassing equity, debt, currency, and commodities. The Company operates through two segments, namely Advisory and Transactional Services, and Financing and Investment Activities. The Advisory and Transactional Services segment consists of broking and distribution of securities, investment banking, and other related financial intermediation services. The Financing and Investment Activities segment engages in non-banking financing activities. Its subsidiaries include Emkay Fincap Limited, Emkay Commotrade Limited, Emkay Wealth Advisory Limited, and Emkay Investment Managers Limited, among others.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Rohit Gupta

Rohit Gupta

20 Nov • 9:19 AM · SEBI-Registered Analyst

Urban Company raises 2,500 crore through QIP

URBANCO Urban Company Limited anounced the successful completion of its Qualified Institutions Placement (“QIP”) of equity shares, raising Rs.2,500 crore. The QIP drew strong, diversified participation from marquee domestic and global institutional investors. As set out in the placement document, the net proceeds will be used for: Building the supply ecosystem for ‘InstaHelp by UC’; Brand marketing and business promotion to increase awareness and visibility of the platform across segments; Technology and cloud infrastructure; Training infrastructure for service professionals; Research and development for Native products; and Potential acquisitions and general corporate purposes. Morgan Stanley India Company Private Limited was the lead book runner for the QIP, ably supported by Kotak Mahindra Capital Company Limited and Emkay Global Financial Services Limited. Shardul Amarchand Mangaldas & Co acted as legal counsel to the Company. Cyril Amarchand Mangaldas acted as Indian legal counsel, and White & Case Pte. Ltd. as international legal counsel, to the Book Running Lead Managers. Opinion :This news will have positive impact on the stock price. Disclaimer : I do not hold this stock. This is not a buy sell or hold recommendation

See More
Inderjeet Singh

Inderjeet Singh

17 Nov • 1:34 PM · SEBI-Registered Analyst

Senco Gold Shares Surge 8% on Record Festive Sales

SENCO Gold shares surged as much as 8.3% to ₹337.50 on November 17 after the jewellery retailer reported its highest-ever sales during the 41-day festive period from October 1 to November 11, 2026. The company recorded retail net sales value (NSV) of over ₹2,426 crore during the Dhanteras and Diwali season, registering a 26% year-on-year growth despite volatile gold prices and elevated costs. However, profit booking trimmed the gains, with shares trading around ₹322.60, up 3.5% during the afternoon session. The strong performance was supported by higher customer footfalls, increased transaction volumes, new customer acquisitions and healthy growth across company-owned and franchise-operated showrooms. Same-store sales growth stood at 17%, while diamond jewellery sales increased 26% in value terms and 18% in volume terms. The company also reported its highest-ever topline of over ₹5,000 crore in the first half of FY27 and crossed ₹10,000 crore in trailing twelve-month sales. Senco Gold opened 10 new showrooms during the festive period and plans to add another three to four outlets. On the brokerage front, Emkay Global retained its 'Buy' rating with a target price of ₹575, citing strong sales growth and expansion opportunities. However, Motilal Oswal maintained a 'Neutral' rating with a target price of ₹350, highlighting concerns over operating margins and the pace of recovery. The company's festive performance has strengthened its growth outlook, although margin improvement remains a key monitorable.

See More
Pankaj Pawar

Pankaj Pawar

13 Nov • 1:12 PM · SEBI-Registered Analyst

Zee approves ₹600 crore buyback at ₹91 per share plan

ZEEL has approved a share buyback worth up to ₹600 crore at a price of ₹91 per share through the tender offer route. Key buyback details: Total buyback size: Up to ₹600 crore. Buyback price: ₹91 per share. Market closing price: ₹73.50. Premium: Approximately 23.8% over the previous NSE closing price. Maximum shares: Up to 6.59 crore equity shares. Capital represented: Up to 6.86% of existing paid-up equity share capital. Record date: November 25, 2026. Small shareholders: 15% of the buyback size or the entitled number of shares has been reserved for small shareholders. Promoter participation: Promoters and promoter group members will not participate. The buyback is a positive shareholder-return initiative. The ₹91 offer price represents a substantial premium to the previous closing price of ₹73.50. The company has cited strong free cash flows and its view that the market valuation is below intrinsic fundamentals. Emkay Global Financial Services has been appointed as the merchant banker. The board has also retained the option to increase the buyback price up to one working day before the record date. However, investors should understand that the 23.8% premium is not a guaranteed return on every shareholding. Actual acceptance will depend on the tender process and acceptance ratio. The buyback will also result in a cash outflow for the company. My View: The ₹600 crore buyback at ₹91 per share is a positive development for ZEEL shareholders. The premium, promoter non-participation and small-shareholder reservation make the offer noteworthy. However, the actual benefit to an investor will depend on the number of shares accepted in the tender offer and the final buyback terms. What to watch: November 25, 2026 record date and shareholder eligibility. Final buyback price and tender-offer schedule. Acceptance ratio, particularly for small shareholders. Impact of the ₹600 crore cash outflow on the company's financial position. Stance: ZEEL – POSITIVE (8/10)

See More
Finkhoz Roboadvisory Services

Finkhoz Roboadvisory Services

2 Nov • 7:34 PM · SEBI-Registered Analyst

Sun Pharma slips 2% as Ilumya sales slow in Q2

SUNPHARMA Limited (SUNPHARMA) traded 1.6% lower at ₹1,749.80 on November 2 after management flagged slower sales of its key specialty drug Ilumya. Reported Q2 FY27 net profit fell 36% to ₹1,988.5 crore, announced on October 30. Revenue grew 11.9% to ₹16,198.7 crore, led by a 17.3% rise in India formulations. US formulation sales fell 8.3%. Profit was hit by ₹1,268.8 crore of one-time charges linked to a US antitrust settlement and the pending Organon acquisition. Adjusted profit rose 1.4% to ₹3,162 crore. The one-time charges explain the headline fall, not the business. The India business is growing strongly, and gross margin improved to 80.8% from 79.3%. Management also reiterated its high single-digit growth guidance for FY27, and 35 of 40 analysts covering the stock rate it a Buy. The concern is Ilumya, which made up 12% of FY26 sales. Its slowdown, along with falling US sales, is squeezing margins. EBITDA grew only 4.8%, and the EBITDA margin slipped to 29.3% from 31.3%. Emkay cut its target to ₹2,000. Investors should watch Ilumya’s psoriatic arthritis launch in November, US sales trends and the Organon deal closing. The key question is whether Ilumya can regain growth fast enough to protect margins. Disclosure: I do not hold any position in Sun Pharmaceutical Industries Limited. This post is for informational purposes only and is not investment advice.

See More
Rahul Porwal

Rahul Porwal

2 Nov • 5:34 PM · SEBI-Registered Analyst

Dixon Technologies’ shares surged 10–12% today

DIXON Dixon Technologies’ shares surged 10–12% today despite a sharp 49% fall in quarterly profit, as investors focused on strong revenue growth (up 47% YoY) and optimism around smartphone recovery and the Vivo joint venture. Brokerages remain bullish, with target prices suggesting up to 45% upside, though analysts warn of margin pressures in the near term. 📊 Dixon Technologies Q2 FY27 Highlights Revenue: ₹21,794 crore, up 46.7% YoY (beat estimates). Net Profit: ₹343.7 crore, down 48.7% YoY. EBITDA: ₹597–666 crore, down 37% YoY. EBITDA Margin: Contracted to 2.7–3.1% (vs 7.1% last year). Smartphone Volumes: Recovery noted, with ~9.5 million units shipped. Operating Profit: ₹597 crore, up 6% YoY. 📈 Market Reaction Share Price Movement: Jumped 10–12% intraday, hitting ₹12,199–₹12,319 on NSE. Market cap crossed ₹72,900 crore. Brokerage Views: Motilal Oswal: Buy, target ₹15,900 (44.5% upside). UBS: Buy, target ₹15,600 (41.8% upside). Nuvama: Upgraded to Buy, target ₹14,900 (35.5% upside). Emkay Global: Buy, target ₹16,400.

See More
Amit Malviya

Amit Malviya

21 Oct • 10:58 AM · SEBI-Registered Analyst

LTTS Q2 Results Surge – Profit Jumps 66.8% YoY!

LTTS L&T Technology Services (LTTS) shares surged over 11–15% today after announcing stellar Q2 FY27 results, with net profit rising 66.8% YoY to ₹548 crore and revenue crossing ₹3,040 crore. The company also declared an interim dividend of ₹20 per share. 📊 LTTS Q2 FY27 Results (Quarter ended Sept 30, 2026) Revenue: ₹3,040 crore (+12.1% YoY, +3.4% QoQ) Net Profit: ₹548 crore (+66.8% YoY, +53.7% QoQ) EBIT Margin: 16.3% (improved 60 bps QoQ) USD Revenue: $317 million (+4.8% YoY in constant currency) Dividend: Interim dividend of ₹20/share (record date: Oct 27, 2026) Large Deals: $200+ million TCV wins, with AI-related deals forming over 50% 🚀 Market Reaction Share Price Surge: LTTS stock jumped as much as 15% intraday, hitting ₹4,140.50 on BSE. 52-Week Range: ₹3,030 – ₹4,746.95 Trend: Strong bullish momentum; analysts expect continued growth in H2 FY27. 🧠 Strategic Highlights AI & Engineering Intelligence (EI): Launched EI Lab with NVIDIA to build AI-native applications in manufacturing, robotics, and supply chain. Filed 250+ AI patents, total portfolio now 1,808 patents. EI-led revenue annualized at $120 million (~9.5% of Q2 revenue). Sectoral Growth: Sustainability vertical delivered strongest growth. Mobility maintained momentum. Tech segment steady with margin improvement. Recognition: Won Gold Award for Industrial Engineering R&D at CII Awards 2026. Recognized as Leader in Everest Group’s PLM Services PEAK Matrix 2026. Nasscom AI Gamechangers Award for PLxAI solution. 📈 Analyst Views JM Financial: Maintains Add rating, raises target price to ₹3,890. Emkay Global: Maintains Add, raises target to ₹3,900. Outlook: Management expects H2 FY27 growth to exceed H1, supported by large-deal conversions and strong backlog. EBIT margins expected to sustain at ~16% despite Q3 wage-hike headwinds.

See More

News & Events

Frequently Asked Questions

What is the share price of Emkay Global Financial Services Ltd.?

What is the market cap of Emkay Global Financial Services Ltd.?

Should I buy Emkay Global Financial Services Ltd. stock now?

What is the 52 week high and low of Emkay Global Financial Services Ltd.?

Is the Emkay Global Financial Services Ltd. stock good to buy?

Is Emkay Global Financial Services Ltd. a good buy for the long term?

Is Emkay Global Financial Services Ltd. overvalued or undervalued?

What is the PE and PB ratio of Emkay Global Financial Services Ltd.?

Start Now